权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A High-Throughput Human Metabolic Stability Assay Chip for Early-Stage Drug Disco

用于早期药物迪斯科的高通量人体代谢稳定性检测芯片

基本信息

批准号：
7394070
负责人：
MOO-YEAL LEE
金额：
$ 20.06万
依托单位：
SOLIDUS BIOSCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-02-05 至 2010-02-04
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7394070
关键词：
Address Adoption Biological Assay California Catalysis Cells Chemicals Clinical Trials Combinatorial Synthesis Consumption Coupled Couples Cytochrome P450 Decision Making Development Devices Drug Delivery Systems Drug Formulations Drug Industry Drug Stability Environment Enzyme Stability Enzymes Evaluation Failure Fluorescence Glass Goals Human Human body Hydrogen Peroxide Individual Institutes Investments Lead Liver Measurement Medicine Metabolic Metabolism Methods NADP New Drug Approvals Numbers Optics Outcome Oxygen Patients Pharmaceutical Preparations Pharmacologic Substance Pharmacotherapy Phase Population Predisposition Preparation Process Productivity Protein Isoforms Public Health Rate Reaction Relative (related person)Research Research Personnel Risk Safety Science Screening procedure Slide Small Business Technology Transfer Research Speed Staging Subgroup System Techniques Technology Time Toxic effect Toxicology Translating Treatment Protocols United States National Institutes of Health Universities analog base design drug development drug discovery drug metabolism high throughput analysis high throughput technology in vivo oxidation programs tool

项目摘要

DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with the University of California, Berkeley, and Rensselaer Polytechnic Institute are proposing to address a critical need in drug safety technology through its proprietary "metabolic stability" chip (or Metabolizing Enzyme Stability Assay Chip, or MesaChip) for high-throughput analysis of drug candidate metabolism. The MesaChip is being developed to provide the pharmaceutical industry user with the ability to mimic the first-pass metabolism of the human liver. While in recent years there has been a dramatic increase in the number of new chemical entities (NCEs) and screenable drug targets, such increases in productivity have not translated into an increased number of new drug approvals, in part because of the high failure rate due to toxicity of the NCE or its metabolite(s). A critical component of drug safety evaluation is the metabolic stability of a drug candidate, which reflects the susceptibility of a drug candidate to be metabolized and the rate of such metabolism. Early stage metabolic stability analysis, however, is currently limited by the inherent low throughput of methods available that provide accurate quantitative measurement of drug candidate metabolism. As a result, accurate information required for early-stage high-quality decision making is lacking. The specific aims of this Phase I project are to: 1. Develop well-based fluorescence assays that enable determination of P450-catalyzed substrate oxidation rates from concurrent measurements of oxygen and NADPH consumption and of H2O2 formation. 2. Verify using LC-MS that the above rate measurements can be used to calculate accurate rates of P450-catalyzed oxidation reactions. 3. Adapt the well-plate assay techniques developed in Aim 1 to a high-throughput microarray format (MesaChip) based on the MetaChip platform that involves P450s incorporated into microspots (< 30 nL) on a functionalized glass slide. Once fully developed, the MesaChip will provide a robust and high-throughput technology platform capable of providing pharmaceutical researchers with the information needed to predict the in vivo metabolic stability of drug candidates, and thus help to decide which compounds are brought forward for lead optimization. This capability is also a critical precursor to the widespread adoption of personalized medicine, where differences among individuals in drug metabolism can be predicted, thereby providing information on the potential outcome of drug therapy at the individual patient level. The goals of this STTR project, therefore, fit the goals of the National Institutes of Health. The drug discovery process is an investment-intensive, high-risk endeavor that results in low yields of effective and safe drugs; a problem that is confounded by the significant lack of information that exists in predicting the metabolic fate of drug candidates, in general, and in predicting the reactivity of drug candidates in the human body. The proposed STTR project for the development of Solidus Bioscience's MesaChip technology has significant relevance to public health by providing pharmaceutical researchers with the information needed to predict the in vivo metabolic stability of drug candidates, and thus help to decide which compounds are brought forward for lead optimization and the ultimate development of better and safer drugs.

描述（由申请人提供）：Solidus Biosciences，Inc.与加州大学伯克利分校和伦斯勒理工学院合作，提出通过其专有的“代谢稳定性”芯片（或代谢酶稳定性分析芯片，或MesaChip）来解决药物安全技术的关键需求，用于候选药物代谢的高通量分析。正在开发的MesaChip为制药行业用户提供模拟人类肝脏首过代谢的能力。虽然近年来新化学实体（NCE）和可筛选药物靶标的数量急剧增加，但生产率的提高并没有转化为新药批准数量的增加，部分原因是由于NCE或其代谢物的毒性导致的高失败率。药物安全性评价的一个关键组成部分是候选药物的代谢稳定性，它反映了候选药物被代谢的敏感性和这种代谢的速率。然而，早期代谢稳定性分析目前受到提供候选药物代谢的准确定量测量的可用方法的固有低通量的限制。因此，缺乏早期高质量决策所需的准确信息。第一阶段项目的具体目标是：1.开发基础良好的荧光分析，能够通过同时测量氧气和NADPH消耗以及H2 O2形成来确定P450催化的底物氧化速率。2.使用LC-MS验证上述速率测量值可用于计算P450催化氧化反应的准确速率。3.将目标1中开发的孔板测定技术调整为基于MetaChip平台的高通量微阵列格式（MesaChip），其涉及将P450掺入功能化载玻片上的微点（< 30 nL）中。一旦完全开发，MesaChip将提供一个强大的高通量技术平台，能够为制药研究人员提供预测候选药物体内代谢稳定性所需的信息，从而帮助决定哪些化合物被提出用于先导优化。这种能力也是广泛采用个性化医疗的关键先导，其中可以预测个体之间药物代谢的差异，从而提供关于个体患者水平上药物治疗的潜在结果的信息。因此，这个STTR项目的目标符合美国国立卫生研究院的目标。药物发现过程是一个投资密集型，高风险的奋进，导致低产量的有效和安全的药物;一个问题，是混淆的显着缺乏信息，存在于预测代谢的候选药物的命运，一般来说，并在预测候选药物在人体中的反应。拟议中的STTR项目用于开发Solidus Bioscience的MesaChip技术，通过为制药研究人员提供预测候选药物的体内代谢稳定性所需的信息，从而有助于决定哪些化合物被提出用于先导优化和最终开发更好，更安全的药物，对公共卫生具有重要意义。